Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 13, 2017. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain corporate financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share transactions.
| Transaction Date | Instrument | Transaction Type | Price per Share | Total Volume |
|---|---|---|---|---|
| October 12, 2017 | Ordinary Shares (25p each) | Acquisition via Dividend Re-investment | £15.2659 | 6,534.108 shares |
Note: The total volume is the aggregate of individual transactions listed below.
Material Changes and Transaction Details
The filing reports the acquisition of ordinary shares by eight individuals (seven PDMRs and one associated person) following the re-investment of dividends paid on October 12, 2017. All transactions occurred on the London Stock Exchange (XLON) at a uniform price of £15.2659.
- Ms E Walmsley (CEO): 408.631 shares
- Mr R G Connor (President, Global Manufacturing & Supply): 71.145 shares
- Mr L Debruyne (President, Global Vaccines): 735.251 shares
- Mr S Dingemans (CFO): 793.924 shares
- Mr D S Redfern (Chief Strategy Officer): 1,340.169 shares
- Ms C Thomas (SVP, HR): 517.830 shares
- Mr P C Thomson (President, Global Affairs): 628.735 shares
- Mrs K Thomson (PCA of Mr P C Thomson): 118.755 shares
- Dr P J T Vallance (President, R&D): 2,519.628 shares
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a regulatory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the dividend payment date of October 12, 2017, to confirm the timing of the re-investment.
- Confirm the market price of GSK ordinary shares on the London Stock Exchange on October 12, 2017, matches the reported £15.2659.
- Review the company's annual report (Form 20-F) for broader financial performance metrics not included in this transaction notification.
- Check subsequent filings for any changes in the shareholdings of the listed PDMRs.